



Nancy M. Holekamp, M.D.

Director Retina Service, Pepose Vision Institute

www.peposevision.com



Curriculum Vitae

Present Position

Director, Retina Services – Pepose Vision Institute, St. Louis, MO
Professor, Clinical Ophthalmology, Washington University School of Medicine, St. Louis, MO
Consultant, Lifelong Vision Foundation; Principal Investigator, Clinical Research, St. Louis, MO

Education

Pre-Medical **Wellesley College**, Wellesley, MA
B.A. Molecular Biology, *Summa cum laude* - June, 1985

Medical **The Johns Hopkins University School of Medicine**, Baltimore, MD
M.D. with honors - June, 1989

Internship Department of Internal Medicine
Washington University School of Medicine, St. Louis, MO July 1989 - June 1990

Residency Department of Ophthalmology
Washington University School of Medicine, St. Louis, MO July 1990 - June 1993

Fellowship **Retina Consultants, Ltd.**
St. Louis, MO
July, 1993 - March 31, 1995

Selected Honors and Scholarships

Professor of Clinical Ophthalmology, Washington University School of Medicine
Fifteen-Year Clinical Faculty Award, Washington University 2010
American Academy of Ophthalmology Senior Honor Award 2007
American Academy of Ophthalmology Secretariat Award 2007
America's Best Doctors 2005 to present
Alpha Omega Alpha, 1989
Graduated in top 5 of class, Johns Hopkins School of Medicine, 1989
Marshall Scholar Reserve, 1985
Graduated Summa Cum Laude, Wellesley College, 1985
Graduated with Honors in Molecular Biology, 1985
Phi Beta Kappa, 1985

Certification

FLEX Part I and Part II, 1990
American Board of Ophthalmology, 1994; recertified 2004

Licensure

State of Missouri
State of Illinois

Professional

Diplomat, American Academy of Ophthalmology (AAO)

Organizations and Activities

Missouri Society of Eye Physicians and Surgeons Board 2008 to 2011
AAO BCSC Author, Section 12 – Retina 2006-2009
AAO Secretariat for State Affairs, 2005 to 2010
AAO Ethics Committee member 1999-2005
AAO Leadership Development Program 2004-2005
St. Louis Ophthalmological Society 1995 to present
American Society of Retina Specialists 1995 to present
Women in Retina, Co-Founder 2007 to present
Macula Society, Executive Committee 2006-2009
Retina Society
Editorial Board, *American Journal of Ophthalmology*
Editorial Board, EYENET Magazine
Reviewer, *Archives of Ophthalmology*
Reviewer, *Ophthalmology*
Reviewer, *Retina*
Retinal Advisory Council, Alcon Pharmaceutical Co. 2002-2008
Ophthalmologist Advisory Board, Genentech Pharmaceutical Co. 2006-2013
Ophthalmologist Advisory Board, Allergan Pharmaceutical Co. 2008-2013

Recent Lectures and Presentations (#94 through #100)

94. **Women in Ophthalmology Annual Meeting**, Williamsburg | Virginia | August 2012
- Genetic Testing in AMD
95. **ASRS Annual Meeting**, Las Vegas | Nevada | August 2012
- Real-world Utilization of Intravitreal Anti-VEGF Agents in Common Retinal Diseases
96. **Euretina Meeting**, Milan | Italy | September 2012
- A comparison of two commercially available tests for AMD
- Vitrectomy Surgery: Impact on Cataract, Glaucoma and Retinal Disease
- Vitreous Surgery and Ocular Oxygenation
97. **Washington University School of Medicine Grand Rounds** | St. Louis | Missouri
September 2012 - Genetic Testing in AMD
98. **Saint Louis University School of Medicine Grand Rounds** | St. Louis, Missouri | March 2013
- The Implantable Miniature Telescope
99. **The Macula Society Annual Meeting** | Monarch Beach, CA | March 2013
- A Comparison of Two Commercially Available Genetic Tests for AMD

FLEX Part I and Part II, 1990
American Board of Ophthalmology, 1994; recertified 2004

Licensure

State of Missouri
State of Illinois

Professional

Diplomat, American Academy of Ophthalmology (AAO)

Organizations and Activities

Missouri Society of Eye Physicians and Surgeons Board 2008 to 2011
AAO BCSC Author, Section 12 – Retina 2006-2009
AAO Secretariat for State Affairs, 2005 to 2010
AAO Ethics Committee member 1999-2005
AAO Leadership Development Program 2004-2005
St. Louis Ophthalmological Society 1995 to present
American Society of Retina Specialists 1995 to present
Women in Retina, Co-Founder 2007 to present
Macula Society, Executive Committee 2006-2009
Retina Society
Editorial Board, *American Journal of Ophthalmology*
Editorial Board, EYENET Magazine
Reviewer, *Archives of Ophthalmology*
Reviewer, *Ophthalmology*
Reviewer, *Retina*
Retinal Advisory Council, Alcon Pharmaceutical Co. 2002-20008
Ophthalmologist Advisory Board, Genentech Pharmaceutical Co. 2006-2013
Ophthalmologist Advisory Board, Allergan Pharmaceutical Co. 2008-2013

Recent Lectures and Presentations (#94 through #100)

94. **Women in Ophthalmology Annual Meeting**, Williamsburg | Virginia | August 2012
- Genetic Testing in AMD
95. **ASRS Annual Meeting**, Las Vegas | Nevada | August 2012
- Real-world Utilization of Intravitreal Anti-VEGF Agents in Common Retinal Diseases
96. **Euretina Meeting**, Milan | Italy | September 2012
- A comparison of two commercially available tests for AMD
- Vitrectomy Surgery: Impact on Cataract, Glaucoma and Retinal Disease
- Vitreous Surgery and Ocular Oxygenation
97. **Washington University School of Medicine Grand Rounds** | St. Louis | Missouri
September 2012 - Genetic Testing in AMD
98. **Saint Louis University School of Medicine Grand Rounds** | St. Louis, Missouri | March 2013
- The Implantable Miniature Telescope
99. **The Macula Society Annual Meeting** | Monarch Beach, CA | March 2013
- A Comparison of Two Commercially Available Genetic Tests for AMD

1815 Clarkson Road • Chesterfield, MO 63017 • 636.728.0111 • Toll Free : 877.862.2020
13134 Tesson Ferry Road • St. Louis, MO 63128 • 314.375.0111 • Toll Free: 314.722.4320
www.peposevision.com

100. **The University of Kansas Department of Ophthalmology Annual Meeting** | Kansas City, Kansas
 May 2013
 - The Oxygen Hypothesis
 - A Comparison of Two Commercially Available Genetic Tests for AMD

Recent Publications (#55 through #64)

55. **Holekamp NM**, The vitreous gel: more than meets the eye. *American Journal of Ophthalmology*. 149(1):32-6, 2010.
56. **Holekamp NM**, Vitreomacular adhesion in active and end-stage age-related macular degeneration. *American Journal of Ophthalmology*. 149(1):171-2; 2010
57. **Holekamp NM**, Bai F, Shui YB, Almony A, Beebe DC. (2010) Ischemic diabetic retinopathy may protect against nuclear sclerotic cataract. *Am J Ophthalmol*;150(4):543-550.e1, 2010 Oct. NIHMS #207583
58. Siegfried CJ, Shui YB, **Holekamp NM**, Bai F, Beebe DC. (2010) Oxygen Distribution in the Human Eye: Relevance to the Etiology of Open Angle Glaucoma after Vitrectomy. *IOVS* Nov. 2010 51:5731-5738
59. Beebe, DC, **Holekamp NM**, Shui, Y-B. (2010). Oxidative Damage and the Prevention of Age-Related Cataracts. *Ophthalmic Res*. 44(3):155-65, 2010.
60. Beebe, DC, **Holekamp NM**, Siegfried, CJ, Shui, Y-B. (2010). Vitreoretinal influences on lens function and cataract. *Trans. Roy. Acad. Sci. Ser. B. Phil. Trans. R. Soc. B* 2011 **366**, 1293-1300
61. Werther W, Chu L, **Holekamp NM**, Do D, Rubio R. Myocardial Infarction and Cerebrovascular Accident in Patients With Retinal Vein Occlusion. *Arch Ophthalmol*. 2011; 129:326-331.
62. Siegfried CJ, Shui YB, Bai F, **Holekamp NM**, Beebe DC. (2010). Racial Differences in Ocular Oxidative Metabolism: Implications for Ocular Disease. *Arch Ophthalmol*. 2011 Jul 01
63. Beebe DC, **Holekamp NM**, Siegfried C, Shui YB. *Philos. Trans. R. Soc. Lond., B. Biol. Sci*. 2011
64. Almony, A, **Holekamp NM**, Bai, F, Shui, YB, Beebe, DC. Small-Gauge Vitrectomy Does Not Protect Against Nuclear Sclerotic Cataract. *Retina*. March 2012,32(3):499-505.

Collaborative Clinical Trials

- | | |
|---|------------|
| 1. Submacular Surgery Trials
- Principal Investigator | 1997-2004 |
| 2. Vitrase Phase III Safety and Efficacy of Vitrase (Hyaluronidase) for Ophthalmic Intravitreal Injection for Clearance of Severe Vitreous Hemorrhage Study - #VIT-02-08961X
- Principal Investigator | 1998- 2003 |
| 3. Complications of ARMD Prevention Trial (CAPT),
- Sub-investigator | 1999-2006 |
| 4. Safety and Efficacy of Anecortave Acetate vs. Placebo when Injected Sub-Tenon's in Patients with Subfoveal AMD – Protocol Number C-98-03
- Sub-investigator | 2000-2003 |
| 5. A Phase III, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) in Subjects with Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration – Protocol Number FVF2598g (MARINA) | |

- Sub-investigator 2003-2005
- 6. A Phase I/II, Single-Masked, Multicenter Study of the Safety, Tolerability, and Efficacy of Multiple-Dose Intravitreal Injections of rhuFab V2 in Combination with Verteporfin (Visudyne®) Photodynamic Therapy in Subjects with Neovascular Age-Related Macular Degeneration (FOCUS)
- Sub-investigator 2003-2006
- 7. An Evaluation of Efficacy and Safety of Posterior Juxtapapillary Administrations of Anecortave Acetate for Depot Suspension (15 mg or 30 mg) versus Sham Administration in Patients (Enrolled in Study "A" or Study "B") at Risk for Developing Sight-Threatening Choroidal Neovascularization (CNV) Due to Educative Age Related Macular Degeneration (AMD) – Protocol Number C-02-60 (Anecortave Acetate Risk Reduction Trial)
- Sub-investigator 2004-Present
- 8. Regeneron: An Exploratory Study of the Safety, Tolerability and Biological Activity of Intravenously Administered in Patients with Diabetic Macular Edema – Protocol Number VGFT-OD-0307 - Principal Investigator 2004-2005
- 9. Allergan: A Six-Month, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficacy of 700µg and 350µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Macular Edema Following Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion –Protocol 206207-008
- Principal Investigator 2004-2009
- 10. SCORE (Standard Care vs. Corticosteroid for Retinal Vein Occlusion) Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide with Standard Care to Treat Macular Edema: One for Central Retinal Vein Occlusion and One for Branch Retinal Vein Occlusion
- Sub-investigator 2004-Present
- 11. Choroidal Neovascularization Assessment by Pattern Electroretinography after Ranibizumab in Naive Age-related Macular Degeneration Patients (Protocol #FVF4184S, CAPTAIN)
- Sub-investigator 2007-Present
- 12. Age-Related Eye Disease Study II (AREDS II): A Multi-Center Randomized Trial of Lutein, Zeaxanthin, and Omega-3 Long-Chain Polyunsaturated Fatty Acids (Docosahexaenoic Acid [DHA] and Eicosapentaenoic Acid [EPA] in Age-Related Macular Degeneration
- Sub-investigator 2007- Present
- 13. A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Subjects with Macular Edema Secondary to Branch Retinal Vein Occlusion (Protocol FVF4165g - BRAVO)
- Sub-investigator 2008 - Present
- 14. A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion (Protocol FVF4166g - CRUISE)
- Sub-Investigator 2008-Present
- 15. Comparison of Age-Related Macular Degeneration Treatments Trials (CATT): Lucentis-Avastin Trial
- Sub-Investigator 2008-Present
- 16. A Phase III, Double-Masked, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab Administered Monthly or on an As-Need Basis (PRN) in Patients with Subfoveal Neovascular Age-Related Macular Degeneration (Protocol number is FVF4579g)
- Principal Investigator 2009 - present